Format

Send to

Choose Destination
An Bras Dermatol. 2017 Jan-Feb;92(1):139-141. doi: 10.1590/abd1806-4841.20175070.

Identifying the incidence of rash, Stevens-Johnson syndrome and toxic epidermal necrolysis in patients taking lamotrigine: a systematic review of 122 randomized controlled trials.

Author information

1
Northshore University Health System, University of Chicago Pritzker School of Medicine - Chicago, Illinois.
2
University of California Irvine, Department of Dermatology - Irvine, California.

Abstract

Lamotrigine is an antiepileptic drug used for the treatment of epilepsy, bipolar disorder and numerous off-label uses. The development of rash significantly affects its use. The most concerning of these adverse reactions is Stevens-Johnson syndrome/toxic epidermal necrolysis. We performed a systematic review of randomized controlled trials using lamotrigine as a monotherapy to quantify the incidence of cutaneous reactions, particularly Stevens-Johnson syndrome/toxic epidermal necrolysis. Of a total of 4,364 papers regarding lamotrigine, 122 studies met our inclusion and exclusion criteria. In total, 18,698 patients were included with 1,570 (8.3%) of patients experiencing an adverse dermatologic reaction. The incidence of Stevens-Johnson syndrome/toxic epidermal necrolysis was 0.04%.

PMID:
28225977
PMCID:
PMC5312199
DOI:
10.1590/abd1806-4841.20175070
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Scientific Electronic Library Online Icon for PubMed Central
Loading ...
Support Center